In a pooled analysis of 11 randomized controlled trials involving patients with advanced NSCLC receiving ICI monotherapy, Vallejo et al. reported that higher levels of PD-L1 expression were associated with improved PFS and OS [36]. Here, CD274 is linked to non-small cell lung carcinoma.